NCT04876391: A reported trial by Boehringer Ingelheim
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04876391 |
|---|---|
| Title | An Open-label, Long-term Extension Trial of Spesolimab Treatment in Adult Patients With Hidradenitis Suppurativa (HS) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 24, 2021 |
| Completion date | April 26, 2024 |
| Required reporting date | April 26, 2025, midnight |
| Actual reporting date | April 10, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |